Second-line treatment of metastatic gastric cancer: Current options and future directions - sprookjes - yvandenbroek - TriplyDB

Second-line treatment of metastatic gastric cancer: Current options and future directions

Second-line treatment of metastatic gastric cancer: Current options and future directions

http://www.wikidata.org/entity/Q26778027

about

New advances in targeted gastric cancer treatment KIAA1199 promotes migration and invasion by Wnt/β-catenin pathway and MMPs mediated EMT progression and serves as a poor prognosis marker in gastric cancer.Second Primary Malignancies in Adults with Gastric Cancer - A US Population-Based Study MAGI1 inhibits migration and invasion via blocking MAPK/ERK signaling pathway in gastric cancer Activation of EIF4E by Aurora Kinase A Depicts a Novel Druggable Axis in Everolimus-Resistant Cancer Cells.MicroRNA-200c is involved in proliferation of gastric cancer by directly repressing p27Kip1.TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study.Blockade of ITGA2 Induces Apoptosis and Inhibits Cell Migration in Gastric Cancer.

P2860

Q26738548-8B7F49D0-0AE5-422A-A948-7C6344CC9AFD Q33580666-CF7D6C9F-735C-42E3-B575-724763453B72 Q36784611-73B1B231-E47D-4161-B731-74047824FC91 Q37697309-3D2FB77F-7506-4B9F-B036-E3558EA45392 Q39028389-D6F41430-2A7B-4038-AFAA-F433A6F9961F Q41682632-7808470D-F95B-4275-AD45-115BD12EE1C7 Q55176833-8286FA82-8511-4EF4-84C5-B6E386CDF1F1 Q55313144-701D4BF3-DE12-4540-88B0-C178FB386728

P2860

Second-line treatment of metastatic gastric cancer: Current options and future directions

http://www.wikidata.org/entity/Q26778027

description

2015 nî lūn-bûn

@nan

2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Second-line treatment of metastatic gastric cancer: Current options and future directions

@ast

Second-line treatment of metastatic gastric cancer: Current options and future directions

@en

Second-line treatment of metastatic gastric cancer: Current options and future directions

@nl

type

label

Second-line treatment of metastatic gastric cancer: Current options and future directions

@ast

Second-line treatment of metastatic gastric cancer: Current options and future directions

@en

Second-line treatment of metastatic gastric cancer: Current options and future directions

@nl

prefLabel

Second-line treatment of metastatic gastric cancer: Current options and future directions

@ast

Second-line treatment of metastatic gastric cancer: Current options and future directions

@en

Second-line treatment of metastatic gastric cancer: Current options and future directions

@nl

P1433

Q26778027-3E049900-A17F-4180-B7FB-8504C14408A5

P1476

Q26778027-6CB84149-5394-4833-81D3-E571F228EAB4

P2093

Q26778027-20D9B9E0-C099-4CD6-A95B-93E8C96783D4

Q26778027-73F62E4D-3CEF-4101-94AA-B37FDE16CB6A

Q26778027-CCA66CB3-DF9F-4506-BE61-8B3C6554BA33

Q26778027-D5B70E0C-6887-42FF-8F09-D68EFC0EE5B1

P2860

Q26778027-0204FFF9-C7A2-45A6-9A0C-CCB269F39A36

Q26778027-030D38C9-5A91-4039-988E-13336F78CC4D

Q26778027-039F6770-47B1-446C-88A9-5901B1C27AB5

Q26778027-0497E828-E517-4813-8055-B7A1B101D14D

Q26778027-086244B8-5223-4B5F-BB9A-93C31BE207AA

Q26778027-0C3B396D-74E5-4388-B4BF-FDA0974BE6C0

Q26778027-1329E3A1-6DE9-4D3D-B309-104A80EC10C0

Q26778027-198AEAA2-C3D4-4022-9F5C-57E2BFA7A1DE

Q26778027-1D8AD4FA-4C2B-49E1-8DE5-6C86F90F8E39

Q26778027-25A2BC27-CD9E-4F9B-A95C-1407C01EA699

P304

Q26778027-9EB65E8D-03D2-45D3-8B41-D914D1AB509F

P31

Q26778027-77844D7E-4FE7-4494-A54C-A9B0C0A0CE51

P356

Q26778027-0D65895F-5278-45B7-9B78-64E62E778995

P407

Q26778027-5CE138CB-96BD-4C6E-91A0-5F549C58C7AC

P433

Q26778027-21063BC5-33DA-4729-A5FC-30365A805B79

P478

Q26778027-B7C62554-BC8A-4D2D-84D7-D714FE28429F

P577

Q26778027-BF1E9991-2A19-4015-ACC6-6EF3AA0EAAD6

P5875

Q26778027-CB1F9473-418D-47A9-A590-032977732CDA

P698

Q26778027-0999F8B0-F7F7-44AF-9C57-BBF0D4BD38DC

P932

Q26778027-7BDDE3DE-A038-433E-A33E-AC649209223F

P356

WJG.V21.I41.11621

P1433

World Journal of Gastroenterology

P1476

Second-line treatment of metastatic gastric cancer: Current options and future directions

@en

P2093

Alexey Tryakin

http://www.w3.org/2001/XMLSchema#string

Dheepak Kanagavel

http://www.w3.org/2001/XMLSchema#string

Mikhail Fedyanin

http://www.w3.org/2001/XMLSchema#string

Sergei Tjulandin

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy for advanced gastric cancer

Receptor specificity of the fibroblast growth factor family

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.

Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012

Identification of a new fibroblast growth factor receptor, FGFR5

Comprehensive molecular characterization of gastric adenocarcinoma

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

P304

11621-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V21.I41.11621

http://www.w3.org/2001/XMLSchema#string

P407

P433

41

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2015-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

283618062

http://www.w3.org/2001/XMLSchema#string

P698

26556991

http://www.w3.org/2001/XMLSchema#string

P932

4631965

http://www.w3.org/2001/XMLSchema#string